Novartis' CAR-T Kymriah has become the first therapy in the category to be approved for the treatment of relapsed/refractory follicular lymphoma, ahead of Gilead Sciences' rival Yescarta. Follicular ...
DALLAS — A cementless, anatomic ceramic hip resurfacing device may be safe and effective, with a low all-cause revision rate at 8-year follow-up, according to results presented here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback